Similarly, carfilzomib is associated to thrombotic microangiopathy likely due to excessive complement activation, reduction of vascular endothelial growth factor (VEGF) levels via NF-κB inhibition and endothelial injury (17). This evidence concerns the gene NFKB1 and Genetic thrombotic microangiopathy.